US-based health behaviour tracking platform Evidation Health has received $30m in a series C round featuring power and industrial technology producer General Electric (GE) and pharmaceutical firm Sanofi.
B Capital Group, the venture capital firm backed by consulting firm Boston Consulting, co-led the round with VC firm SV Health Investors, while the corporates invested through subsidiaries GE Ventures and Sanofi Ventures respectively.
Formed in 2012 through a partnership between GE Ventures and Stanford University, Evidation has built a software platform that tracks data from mobile devices and connected sensors such as wearable and medical devices to analyse consumer health behaviour.
The technology is utilised by healthcare companies to discover how medical treatments can be better administered and which work most effectively. It has just introduced a data analysis platform to help users better understand large-scale health data.
Deborah Kilpatrick, chief executive of Evidation, said: “Our new data platform makes it easier for statisticians and data scientists at life sciences and healthcare companies to take everyday behaviour and healthcare data, analyse it and create a new understanding of health.
“This will help Evidation speed a transformation in real world research and knowledge, so we can better treat, diagnose and predict the onset of disease.”
The round took Evidation’s overall funding to $61m altogether, $6m of which was raised from GE Ventures, Rock Health Seed Fund and Asset Management Ventures (AMV) in 2015.
B Capital Group led a $15m round for the company in late 2016 that included GE Ventures, AMV, Fresco Capital and Pappas Ventures, before Evidation added $10m in a May 2017 round led by Sanofi Ventures and backed by GE Ventures and B Capital.